Cipla Ltd (CIPLA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500087 | NSE: CIPLA | Pharmaceuticals & Drugs | Large Cap

Cipla Share Price

1,526.80 5.60 0.37%
as on 05-Dec'25 14:00

Cipla Ltd (CIPLA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 500087 | NSE: CIPLA | Pharmaceuticals & Drugs | Large Cap

DeciZen - make an informed investing decision on Cipla

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Cipla stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
22.58
Market Cap:
1,22,878.2 Cr.
52-wk low:
1,310.1
52-wk high:
1,672.2

Is Cipla Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Cipla: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Cipla Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 13.2%8.3%10.2%11.9%12.5%17.9%17.2%18.2%22.8%23.6%-
Value Creation
Index
0.2-0.3-0.10.10.10.60.50.61.01.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 13,59514,39415,15616,36217,13219,16021,76322,75325,77427,54827,844
Sales YoY Gr.-5.9%5.3%8%4.7%11.8%13.6%4.6%13.3%6.9%-
Adj EPS 15.411.416.516.417.129.13032.749.363.867.4
YoY Gr.--26.4%45.1%-0.2%3.9%70.4%3.2%8.9%50.8%29.4%-
BVPS (₹) 142.2155.2175.9185.6194.9226.7257.8289.2329.7384.8407.5
Adj Net
Profit
1,2399141,3271,3251,3772,3472,4222,6383,9785,1505,441
Cash Flow from Ops. 1,7412,3821,4631,6913,0683,7553,3263,2384,1345,005-
Debt/CF from Ops. 31.72.82.60.90.50.30.20.10-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.2%10%8.2%6.9%
Adj EPS 17.1%30.1%28.5%29.4%
BVPS11.7%14.6%14.3%16.7%
Share Price 9% 14.8% 11% 1.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
11.17.69.99.1913.812.411.915.917.817
Op. Profit
Mgn %
18.217.618.718.918.722.220.721.924.425.925.9
Net Profit
Mgn %
9.46.68.88812.211.311.715.618.819.5
Debt to
Equity
0.50.30.30.30.20.100000
Working Cap
Days
220200210151140134135146145155155
Cash Conv.
Cycle
10710610359535256524954117

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Cipla Ltd.

Standalone Consolidated
TTM EPS (₹) 67.3 67.4
TTM Sales (₹ Cr.) 17,386 27,844
BVPS (₹.) 411.6 407.5
Reserves (₹ Cr.) 33,083 32,757
P/BV 3.70 3.73
PE 22.60 22.58
From the Market
52 Week Low / High (₹) 1310.05 / 1672.20
All Time Low / High (₹) 2.22 / 1702.00
Market Cap (₹ Cr.) 1,22,878
Equity (₹ Cr.) 161.6
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Cipla:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Cipla - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Cipla

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales13,59514,39415,15616,36217,13219,16021,76322,75325,77427,548
Operating Expenses 11,11511,91912,32913,26513,95114,91117,25117,76319,48320,420
Manufacturing Costs1,2691,4451,5191,6201,6991,5151,7841,9442,1442,291
Material Costs5,0905,3175,4385,7845,9917,3528,4968,2528,8208,929
Employee Cost 2,4342,6342,6902,8573,0273,2523,5303,8304,3104,833
Other Costs 2,3222,5232,6813,0043,2332,7933,4423,7374,2094,367
Operating Profit 2,4802,4762,8263,0973,1814,2494,5124,9906,2917,128
Operating Profit Margin (%) 18.2%17.2%18.6%18.9%18.6%22.2%20.7%21.9%24.4%25.9%
Other Income 208229358477369270322512747862
Interest 2071591141681971611061109062
Depreciation 7541,3231,3231,3261,1751,0681,0521,1721,0511,107
Exceptional Items 00-78000-182-182-1950
Profit Before Tax 1,7271,2221,6692,0792,1783,2903,4934,0385,7026,821
Tax 3321802505706318899341,2031,5471,530
Profit After Tax 1,3951,0421,4191,5101,5472,4012,5592,8354,1555,291
PAT Margin (%) 10.3%7.2%9.4%9.2%9.0%12.5%11.8%12.5%16.1%19.2%
Adjusted EPS (₹)16.912.517.519.019.229.831.234.751.165.3
Dividend Payout Ratio (%)12%16%17%16%21%17%16%24%25%25%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 11,42712,48214,16314,95515,71018,28420,79823,34626,62031,079
Share Capital 161161161161161161161161161162
Reserves 11,26612,32114,00214,79415,54918,12320,63623,18526,45830,918
Minority Interest3504383523322942592763069696
Debt5,1924,1134,0984,3162,8161,53781018824792
Long Term Debt2223,6453,6623,8302,3691,2034160012
Short Term Debt4,97046743648644733539318824780
Trade Payables1,4761,5712,1191,9482,2822,0672,5082,5352,4742,837
Others Liabilities 2,6052,2651,9402,2102,3202,6892,2612,6332,6932,637
Total Liabilities 21,04920,86922,67323,76223,42324,83726,65229,00732,13036,742

Fixed Assets

Gross Block10,16811,35312,96013,79014,91415,64716,96817,20518,16119,656
Accumulated Depreciation7991,6103,0114,2345,3096,2177,3117,9958,5739,708
Net Fixed Assets 9,3689,7439,9499,5579,6049,4309,6589,2109,5879,948
CWIP 2,0611,6839816768259697661,0931,1531,566
Investments 7589731,2592,5541,4712,7102,5513,6625,4497,933
Inventories3,8083,4854,0453,9654,3784,6695,3505,1565,2385,642
Trade Receivables2,3562,5633,1024,1513,8913,4463,4244,0574,7715,506
Cash Equivalents 8716249666191,0041,4011,9281,565875800
Others Assets 1,8271,7972,3712,2412,2502,2122,9754,2635,0575,347
Total Assets 21,04920,86922,67323,76223,42324,83726,65229,00732,13036,742

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 1,7412,3821,4631,6913,0683,7553,3263,2384,1345,005
PBT 1,7271,2221,6692,0792,1783,2903,6754,2215,8976,821
Adjustment 9511,3741,2941,2691,3661,131967878641518
Changes in Working Capital -429235-778-1064373372-177-559-806-665
Tax Paid -508-450-722-593-848-1,037-1,140-1,302-1,597-1,668
Cash Flow From Investing Activity -4,523-1,310-854-1,669104-2,387-1,872-2,389-2,988-3,691
Capex -1,053-1,098-739-504-986-791-681-1,134-1,315-1,504
Net Investments -0-64-282-1,0641,029-1,675153-913-1,473-2,256
Others -3,470-148167-1016180-1,343-341-20068
Cash Flow From Financing Activity 3,104-1,326-385-349-2,949-1,240-1,600-958-1,200-1,293
Net Proceeds from Shares 31200000000
Net Proceeds from Borrowing -663,420-3-58-1,736-951-1,041-44012
Interest Paid -161-159-118-159-164-121-76-65-65-36
Dividend Paid -159-161-161-242-5640-403-404-686-1,050
Others 3,488-4,438-104109-485-168-80-446-449-219
Net Cash Flow 322-254223-326224129-146-109-5521

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)12.618.7210.6510.3710.0914.1313.112.8516.6318.34
ROCE (%)13.248.2810.211.9412.5317.8517.2418.1922.7723.64
Asset Turnover Ratio0.720.70.71.031.151.171.151.111.161.08
PAT to CFO Conversion(x)1.252.291.031.121.981.561.31.140.990.95
Working Capital Days
Receivable Days58616855544742444551
Inventory Days100919061565862625454
Payable Days10510512412812910898112104109

Cipla Ltd Stock News

Cipla Ltd FAQs

The current trading price of Cipla on 05-Dec-2025 14:00 is ₹1,526.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Cipla stood at ₹1,22,878.2.
The latest P/E ratio of Cipla as of 04-Dec-2025 is 22.60.
The latest P/B ratio of Cipla as of 04-Dec-2025 is 3.70.
The 52-week high of Cipla is ₹1,672.2 and the 52-week low is ₹1,310.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Cipla is ₹17,386 ( Cr.) .

About Cipla Ltd

Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth of complex generics and deepening portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. Equity Shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Limited.

Business area of the company

The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Products

  • Generics and branded generics
  • Specialty
  • Consumer health

Awards:

2013:

  • Ernst & Young awarded Dr. Y K Hamied with the Lifetime Achievement Award of the year 2013
  • Dr. Hamied honoured with the Greatest Global Indian Living Legend Award by NDTV
  • Viragaonagar unit won the Excellence Award in Environment Health & Safety (EHS)
  • Bagged the prestigious LegalEra Award for the Best Pharmaceutical in-house Legal team.

2014

  • Cipla won the Global L&D Team of the Year Award
  • Brand, Azee bagged the Marketing Excellence Award in 2014
  • Won the 'Silver' award from Pharmexcil for Outstanding Performance in the export of Pharmaceuticals
  • Network 18 and Infosys awarded Cipla for innovation on HIV/AIDS drugs

2015:

  • Won the Award for Excellence in Rural Reach at India Pharma Awards
  • Accredited to be in Top 10 of Hot 50 Brands in Mumbai, under ‘Large Organization Category’ at the Mumbai Brand Summit
  • Won the Social Contributors Award at the Annual Pitch Top 50 Brands Awards organized by Dainik Bhaskar
  • Best Company Award to focus in Overall Nursing Home Development at the first ever CIMS Healthcare Excellence Awards
  • ABP News honored Dr. Y.K. Hamied with the ‘Lifetime Achievement Award’ at the Brand Excellence Awards 2015

2016:

  • The Indian Manufacturers’ Association (IDMA) honoured Dr. Hamied with IDMA Lifetime Achievement Award for his outstanding contribution to the Indian pharmaceutical industry.
  • Moroccan Society of ENT honoured Cipla Morocco team for contribution to the education of the physics.
  • Dr. Y.K. Hamied was honoured with the Lifetime Achievement Award at the Forbes India Leadership Awards 2016.
  • Won two awards for Supplier Relationship Management and People Management at the CPO Awards 2016
  • Received an award for Acnedep Gel packaging at the 'India Packaging Awards' 2016
  • Won the ABP News Healthcare Leadership Award for excellence in managing Primary Care Practitioners

2017:

  • Digital team bagged two of the most prestigious awards of the digital world - Digital Pioneer of the year 2017 and Best company for leveraging technology in mobile application.
  • ActivKids Immuno Boosters won the Emerging Nutrition Brand of the Year awarded by CIMS.
  • Cipla Health won a place in the Economic Times Best Asian Healthcare Brands 2017

2018:

  • India Packaging Awards for Excellence in Enhanced User Experience for Mesalo Foam packaging
  • Silver Plasticon Award 2018 for Excellence and Innovation in flexible packaging for Acnedap Plus
  • SCMPro Logistics and Supply Chain Awards for 'Excellence in Pharma Supply Chain Management, Procurement Transformation of the Year' and 'Best Sourcing Analytics'.
  • Global Logistics Excellence Award for 'Best Digital Transformation in Pharma' in the Supply Chain Practitioners category
  • Breathefree website bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category
  • India Pharma Awards for Breathefree - 'Best Patient Outreach Programme of the Year', Digital Innovation
  • Indian Digital Awards (IDA) for Excellence in Digital Publishing
  • ABP News Healthcare Leadership Award for Excellence in Improving Awareness, Detection of Health Issues and Adherence to Treatment Regimen in the Emerging Markets

2019:

  • Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019.
  • Highly Commended - 'Best Working Capital Management Solution Award' at the Adam Smith Awards Asia 2019
  • 'Innovation in Generics' Award for Sereflo at the UK Pharmacy Business Awards 2019
  • ‘Indo-American Corporate Excellence Award' for Excellence in Manufacturing (Category II) by the Indo-American Chamber of Commerce
  • Most Outstanding Company in India - Healthcare category at the Asiamoney Asia’s Outstanding Companies Poll 2019

2020:

  • Cipla Sri Lanka is Great Place to Work Certified
  • Cipla is Great Place to Work Certified
  • ‘Digital Supply Chain Enterprise Award’ at the 9th edition of the Manufacturing Supply Chain Awards 2020
  • Golden Peacock Award for CSR 2019 in recognition of Cipla Foundation's significant contribution towards social change
  • What’s Up Cipla bags the 'Best Small Idea, Big Impact Communication of the Year' at the Corp Comm & PR Excellence Awards 2020
  • The Institute of Chartered Accountants of India Award for Excellence in Financial Reporting 2018-19 under the category of companies publishing integrated annual report

Milestones

  • 1935: Operations commence from a rented bungalow at 289, Bellasis Road, Bombay Central.
  • 1939: Mahatma Gandhi visits Cipla, inspiring the Founder Dr K A Hamied to produce vital and life-saving medicines for India.
  • 1947: Cipla celebrates India attaining Independence with a flag hoisting ceremony at Bombay Central Headquarters.
  • 1970: Cipla becomes one of the pioneers to manufacture APIs (active pharmaceutical ingredients).
  • 1977: Inauguration of the Cipla Research and Production Complex in Bangalore by Mrs. Luba K Hamied.
  • 1997: Cipla Palliative Care and Training Centre is set up in Pune to provide free holistic care to terminally-ill cancer patients and their families.
  • 2001: Cipla ushers in a new paradigm in antiretroviral therapy (ART) by offering the triple ARV FDC at USD 1-a-day, thus opening the floodgates for affordability and accessibility in HIV/AIDS treatment.
  • 2013: Cipla acquires 100% of share capital of Cipla Medpro (South Africa).
  • 2016: Cipla strengthens its presence in the US market with the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. thus expanding its reach in the US market, with a balanced portfolio.
  • 2017: Cipla launches Synchrobreathe, a state of-the-art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
  • 2019: Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
  • 2020: Cipla leads the fight against COVID-19 through a spectrum of vital drugs that show potency against the virus. With unmatched portfolio of drugs and devices and leadership across India and key emerging markets, Cipla launches global lung leadership aspiration - Breathe. Think Cipla. In the US, the approval for generic AIbuterol MDI and successful Phase-3 completion of clinical study for generic Advair Diskus furthers this ambition.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×